EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model



The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model



Pharmaceutical Research 32(2): 665-679



The further characterization of the cell line RPMI 2650 and the evaluation of different culture conditions for an in vitro model for nasal mucosa. Cells were cultured in media MEM or A-MEM at air-liquid (A-L) or liquid-liquid (L-L) interfaces for 1 or 3 weeks. Different cryopreservation methods and cell culture techniques were evaluated with immunolabelling of junctional proteins, ultrastructural analysis using electron microscopy, transepithelial electrical resistance (TEER) measurements, permeation studies with dextran and jacalin, and gene expression profiling of 84 drug transporters. Cell proliferation and differentiation depended on the used medium. The established epithelia expressed occludin, claudin-1, and E-cadherin under all conditions. Cells grown at the A-L interface formed more layers and exhibited a higher TEER and lower dextran and jacalin permeability than at the L-L interface, where cells morphologically exhibited a more differentiated phenotype. The expression of ABC and SLC transporters depended on culture duration and interface. The RPMI 2650 cells form a polarized epithelium resembling nasal mucosa. However, different culture conditions have a significant effect on cell ultrastructure, barrier integrity, and gene expression, and should be considered when using this cell line as an in vitro model for drug permeability studies and screening of nasal drug candidates.

(PDF same-day service: $19.90)

Accession: 056260813

Download citation: RISBibTeXText

PMID: 25145337

DOI: 10.1007/s11095-014-1494-0



Related references

Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions. Journal of Pharmacy and Pharmacology 64(11): 1621-1630, 2013

RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies. European Journal of Pharmaceutics and Biopharmaceutics 74(2): 290-297, 2010

Evaluation of the human cell line RPMI 2650 as an in vitro nasal model. Rhinology 33(4): 194-198, 1995

The novel use of the human nasal epithelial cell line RPMI 2650 as an in vitro model to study the influence of allergens and cytokines on transforming growth factor-beta gene expression and protein release. Clinical and Experimental Allergy 35(6): 811-819, 2005

Cultivation of RPMI 265 cells as an in-vitro model for human transmucosal nasal drug absorption studies optimization of selected culture conditions. 2012

Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. European Journal of Pharmaceutics and Biopharmaceutics 107: 223-233, 2016

Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies. Journal of Pharmaceutical Sciences 97(3): 1165-1178, 2007

Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability. Cytotechnology 65(3): 395-406, 2012

Activity of Multidrug Resistance-Associated Proteins 1-5 (MRP1-5) in the RPMI 2650 Cell Line and Explants of Human Nasal Turbinate. Molecular Pharmaceutics 14(5): 1577-1590, 2017

Cytotoxicity of Different Excipients on RPMI 2650 Human Nasal Epithelial Cells. Molecules 21(5): -, 2016

Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?. European Journal of Drug Metabolism and Pharmacokinetics, 2017

Roles of epidermal growth factor receptor signaling pathway on cultured human nasal epithelial cells RPMI-2650. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 44(3): 203-208, 2011

Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells. International Journal of Pharmaceutics 508(1-2): 22-33, 2016

Expression analysis of human solute carrier (SLC) family transporters in nasal mucosa and RPMI 2650 cells. European Journal of Pharmaceutical Sciences, 2018

The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function. European Journal of Pharmaceutical Sciences 69: 1-9, 2015